Do you want to read an article? Please log in or register.
Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
Glycemic Control
Related content
COMMENTED
Further Publications
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
Lancet Diabetes Endocrinol.
Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, Geer EB, Greenman Y, Witek P, Cohen F, Biller BMK
doi: 10.1016/
COMMENTED
Further Publications
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, LINC 3 investigators
doi: 10.1016/S2213-8587(20)30240-0.
Type 1 Diabetes
Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes Mellitus: Results of the INSTRIDE 3 Phase 3 Switch Study
Diabetes Obes Metab.
Blevins TC, Barve A, Raiter Y, Aubonnet P, Athalye S, Sun B, Muniz R
doi: 10.1111/dom.13904.
Diabetes - GeneralType 2 DiabetesGlycemic Control
A Phase 3, Efficacy and Safety Study of Ertugliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone.
Diabetes Obes Metab.
Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S
doi: 10.1111/dom.12888.
Further Publications
High mortality within 90 days of diagnosis in patients with Cushing's syndrome - Results from the ERCUSYN registry
Eur J Endocrinol.
Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R, Toth M, Zacharieva S, Webb SM, Tsagarakis S, Chanson P, Pfeifer M, Droste M, Komerdus I, Kastelan D, Maiter D, Chabre O, Franz H, Santos A, Strasburger CJ, Trainer PJ, Newell-Price J, Ragnarsson O
doi: 10.1530/EJE-19-0464.
Type 2 Diabetes
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
Diabetes Obes Metab.
Del Prato S, Kang J, Trautmann ME, Stewart J, Sorli CH, Derwahl M, Soto A, Yoon KH
doi: 10.1111/dom.14020.
Type 2 DiabetesGlycemic Control
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Front Endocrinol (Lausanne)
Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG
doi: 10.3389/fendo.2021.662865
Diabetes - General
Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes: An Analysis From the PROSPECT Study
JACC Cardiovasc Imaging.
Farhan S, Redfors B, Maehara A, McAndrew T, Ben-Yehuda O, De Bruyne B, Mehran R, Giustino G, Kirtane AJ, Serruys PW, Mintz GS, Stone GW
doi: 10.1016/
Type 2 DiabetesGlycemic Control
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: results of a 104-week extension to a 52-week randomised, phase 3 study and liver fat MRI sub-study
Diabetes Obes Metab
Frías JP, Maaske J, Suchower L, Johansson L, Hockings PD, Iqbal N, Wilding JPH
doi: 10.1111/dom.14548